Literature DB >> 25498097

Clinical usefulness of oral immunoglobulins in lung transplant recipients with norovirus gastroenteritis: a case series.

A-C Gairard-Dory1, T Dégot2, S Hirschi2, A Schuller2, A Leclercq2, B Renaud-Picard2, B Gourieux1, R Kessler3.   

Abstract

Viral gastroenteritis causing diarrhea is a common complication observed in lung transplant recipients. Differently from the mild and typically self-limited disease seen in immunocompetent subjects, immunocompromised patients frequently have a more severe course. Norovirus and rotavirus are among the leading causes of severe gastroenteritis in transplant recipients. Specific treatment is unavailable, although good supportive treatment can significantly reduce morbidity. Previous studies have suggested that oral immunoglobulins may be used for the treatment of acute viral gastroenteritis after solid-organ transplantation. Herein, we conducted a retrospective chart review of 12 lung transplant recipients with norovirus-induced gastroenteritis who were treated with oral immunoglobulins for 2 days. Eleven patients were successfully treated, whereas 1 subject was only mildly improved. Four patients had at least 1 recurrence. No significant adverse effects were observed. We conclude that oral immunoglobulins may be clinically useful for lung transplant recipients with norovirus-induced gastroenteritis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25498097     DOI: 10.1016/j.transproceed.2014.09.095

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  10 in total

1.  Norovirus in health care and implications for the immunocompromised host.

Authors:  Pearlie P Chong; Robert L Atmar
Journal:  Curr Opin Infect Dis       Date:  2019-08       Impact factor: 4.915

Review 2.  Epidemiology, Clinical Features, and Unusual Complications of Norovirus Infection in Taiwan: What We Know after Rotavirus Vaccines.

Authors:  Meng-Che Lu; Sheng-Chieh Lin; Yi-Hsiang Hsu; Shih-Yen Chen
Journal:  Pathogens       Date:  2022-04-09

Review 3.  Chronic norovirus infection and common variable immunodeficiency.

Authors:  J Woodward; E Gkrania-Klotsas; D Kumararatne
Journal:  Clin Exp Immunol       Date:  2016-11-16       Impact factor: 4.330

Review 4.  Norovirus in Transplantation.

Authors:  Michael P Angarone; Anna Sheahan; Mini Kamboj
Journal:  Curr Infect Dis Rep       Date:  2016-06       Impact factor: 3.725

Review 5.  Human norovirus transmission and evolution in a changing world.

Authors:  Miranda de Graaf; Janko van Beek; Marion P G Koopmans
Journal:  Nat Rev Microbiol       Date:  2016-05-23       Impact factor: 60.633

6.  Severe allograft rejection in an intestinal transplant patient following oral immunoglobulin treatment for chronic norovirus infection: a case report.

Authors:  Fredrik Åberg; Johanna Savikko; Veli-Jukka Anttila; Heikki Mäkisalo
Journal:  Clin Case Rep       Date:  2018-05-11

Review 7.  The Antigenic Topology of Norovirus as Defined by B and T Cell Epitope Mapping: Implications for Universal Vaccines and Therapeutics.

Authors:  Jessica M van Loben Sels; Kim Y Green
Journal:  Viruses       Date:  2019-05-10       Impact factor: 5.048

8.  Llama nanoantibodies with therapeutic potential against human norovirus diarrhea.

Authors:  Lorena Garaicoechea; Andrea Aguilar; Gabriel I Parra; Marina Bok; Stanislav V Sosnovtsev; Gabriela Canziani; Kim Y Green; Karin Bok; Viviana Parreño
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

Review 9.  Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future.

Authors:  Souvik Ghosh; Yashpal Singh Malik; Nobumichi Kobayashi
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

Review 10.  Norovirus in Cancer Patients: A Review.

Authors:  Divya Samantha Kondapi; Sasirekha Ramani; Mary K Estes; Robert L Atmar; Pablo C Okhuysen
Journal:  Open Forum Infect Dis       Date:  2021-03-14       Impact factor: 3.835

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.